Business
Physiomics Awarded Multiple Contract Awards
Physiomics plc has announced the award of multiple new contracts this month with a combined value exceeding £345,000, including engagements with UK and international biotechnology and oncology-focused organisations, and a NASDAQ-listed company. These projects, which will leverage the company's expertise in modelling, simulation, biometrics, and data science, are expected to generate revenue through to the end of 2027, supporting key stages of drug development such as Phase 1 and 2 data analysis and dose selection. The company views these contract wins as a demonstration of its growing client relationships and scientific reputation. Disclaimer*
About this update from Physiomics Plc
27 May 2026 Physiomics plc ("Physiomics" or the "Company") Physiomics Awarded Multiple New Contracts Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far this month, it has secured multiple new contract awards with a combined value of over £345,000. The awards comprise a combination of new and follow-on engagements with respected UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage biotechnology company, clinical-stage therapeutics developers, and leading cancer research groups. The contracts further reinforce Physiomics' growing reputation as a trusted scientific partner across the biotech and pharmaceutical sectors. The projects will utilise the Company's expertise across modelling and simulation, biometrics and data science to support key stages of drug development, including Phase 1 and 2 clinical data analysis, first-in-human dose selection and ongoing clinical programme support. Several of these projects are expected to commence imminently, and provide revenue through to the end of 2027, thus providing near-term revenue and medium-term revenue visability. The Board believes these contract awards also serve to demonstrate the increasing depth and quality of the Company's client relationships. Dr Peter Sargent, CEO of Physiomics, commented: "We are delighted to have secured these contract awards. They reflect our continued investment in business development and marketing, as well as the team's success in expanding and diversifying our pipeline. These opportunities further strengthen our order book and improve revenue visibility across the business. Our broader pipeline remains strong and we're excited about a number of additional opportunities that we hope to be able to announce soon". Hayley Close, Head of Business Development, added: "We are very pleased to have been awarded these new contracts which include both new and existing clients. The continued expansion of our client network, including engagement with larger international companies, reflects the strengthening of our scientific reputation, development of successful long-term relationships and growing awareness of Physiomics within the biotech and pharmaceutical sectors." ENDS For more information about Physiomics and its services, please visit www.physiomics.co.uk . Enquiries: Physiomics plc Mike Whitlow Email: [email protected] Strand Hanson Ltd (NOMAD) James Dance & James Bellman Tel: + 44 (0) 20 7409 3494 Hybridan LLP (Broker) Claire Louise Noyce Tel: +44 (0) 20 3764 2341 About Physiomics Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.